What risks exist with long-term MAT?

Long-term medication-assisted treatment can involve risks related to medication side effects, physical dependence, overdose potential, medication interactions, and ongoing neurological adaptation depending on the medication involved. Methadone, buprenorphine-based medications, and naltrexone each carry different pharmacological risks because they affect opioid receptors and addiction-related neurological pathways differently. The severity of risk is often influenced by polysubstance use, psychiatric symptoms, medical conditions, and treatment stability.

Methadone carries greater overdose and respiratory depression risk compared to buprenorphine because it is a full opioid agonist without the same ceiling effect on opioid activation. Cardiac rhythm abnormalities, sedation, constipation, sweating, hormonal changes, and medication interactions may also occur during long-term methadone treatment. Overdose risk increases substantially when methadone is combined with alcohol, benzodiazepines, or other sedatives.

Buprenorphine-based medications generally have a lower overdose risk profile because of their partial opioid agonist activity and ceiling effect on respiratory depression. However, physical dependence, withdrawal symptoms, sedation, constipation, sleep disruption, and medication interactions may still occur. Long-term opioid receptor activation can also affect nervous system adaptation and tolerance patterns.

Naltrexone-based treatments involve different risks because the medication blocks opioid receptors rather than activating them. Reduced opioid tolerance during naltrexone treatment may increase overdose vulnerability if opioids are later used after treatment interruption. Liver function concerns may also be considered in some individuals receiving long-term naltrexone therapy.

Long-term MAT risks are generally evaluated within the broader context of untreated addiction, relapse vulnerability, overdose mortality, infectious disease exposure, and chronic opioid use disorder severity. Research has consistently shown that medication-assisted treatment reduces many high-risk outcomes associated with uncontrolled opioid addiction. Risk assessment therefore commonly balances medication-related risks against the significantly greater dangers associated with untreated substance use disorders.